메뉴 건너뛰기




Volumn 126, Issue 19, 2001, Pages 547-550

Switch from ACE inhibitor, calcium channel blocker or β-blocker to candesartan cilexetil: Better efficacy and tolerability - SWITCH study (German part);Wechsel von ACE-hemmer, ca-antagonist oder β-blocker zu candesartancilexetil: Bessere wirksamkeit und verträglichkeit - SWITCH-studie (deutscher studienteil)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

EID: 0035843826     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-13808     Document Type: Article
Times cited : (9)

References (11)
  • 2
    • 0001544508 scopus 로고    scopus 로고
    • Continuation of initial antihypertensive medication after 1 year of therapy
    • (1998) Clin Therap , vol.17 , pp. 1-11
    • Bloom, B.S.1
  • 10
    • 0031855691 scopus 로고    scopus 로고
    • Start of therapy with the angiotensin II antagonist losartan after immediate switch from pretreatment with an ACE inhibitor
    • (1998) Br J Clin Pharmacol , vol.46 , pp. 169-172
    • Scholze, J.1    Stapff, M.2
  • 11
    • 0030699197 scopus 로고    scopus 로고
    • Candesartan cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension
    • (1997) J Hum Hypertens , vol.11
    • Zanchetti, A.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.